Mark Stein

Associate Professor

Columbia University Irving Medical Center
Country flagUnited States
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (11)

Differential gene expression analysis, including top 1,000 differentially expressed genes for each cluster (compared with all other clusters) for graph-based clustering of nonimmune cells related to, related to Figure 4. Positive log fold-change (per cluster) indicates upregulation in cluster of interest compared to all other nonimmune clusters.

Year:

2025

Differential gene expression analysis, including top 1,000 differentially expressed genes for each cluster (compared with all other clusters) for graph-based clustering of myeloid cells, related to Figure 4. Positive log fold-change (per cluster) indicates upregulation in cluster of interest compared to all other myeloid clusters.

Year:

2025

Differential gene expression analysis, including top 1,000 differentially expressed genes for each cluster (compared with all other clusters) for graph-based clustering of T cells, related to Figure 5. Positive log fold-change (per cluster) indicates upregulation in cluster of interest compared to all other T cell clusters.

Year:

2025

Differential gene expression analysis based on bulk RNA-seq, including differentially expressed genes for patients with complete or partial response compared to patients with progressive disease, related to Figure 2. Positive log fold-change indicates upregulation in responders.

Year:

2025

Differential gene expression analysis, including differentially expressed genes for ZNF683+ SLAMF7+ CD8+ Exhausted T cells compared to all other T cell clusters, related to Figure 5. Positive log fold-change (per cluster) indicates upregulation in ZNF683+ SLAMF7+ CD8+ Exhausted T cells.

Year:

2025

Immune checkpoint inhibitors targeting the PD-1 pathway have transformed treatment of advanced renal cell carcinoma (RCC), but mechanisms underlying the therapeutic response remain largely unknown. In this study, we perform transcriptomic analysis on RCC biospecimens from 102 patients enrolled in a phase II clinical trial of first-line nivolumab (NCT03117309) to investigate determinants of response to anti–PD-1 monotherapy. Through bulk analysis, we identify an enrichment of genes associated with tertiary lymphoid structures (TLS) in responding patients. Using single-cell transcriptomics and external cohort validation, we identify a population of tissue-resident ( ZNF683 + SLAMF7 + ) exhausted CD8 + T cells enriched in patients with poor clinical outcomes. Integrating these findings, we find tumors with high TLS and low tissue-resident exhausted CD8 + T cells that have superior clinical outcomes with nivolumab. Altogether, these analyses contribute to a growing understanding of how the tumor microenvironment drives immune checkpoint inhibitor resistance and propose possible therapeutic targets to rationally overcome resistance to anti–PD-1 monotherapy. Significance: We describe a paradigm wherein combined high TLS and low tissue-resident exhausted CD8 + T cells are required for optimal response to PD-1 blockade in RCC. This analysis identifies key determinants of response to PD-1 blockade in advanced RCC and suggests avenues for future immune modulation through rational combination therapy strategies.

Year:

2025

Geometric mean fold changes in ( A ) blood RNA, ( B ) IP-10, ( C ) IFNγ, ( D ) IL6, and ( E ) CRP in participants in arms 1, 2, and 4. Data are 6 hours postdose vs. predose for blood RNA and time point vs. predose for other biomarkers. pembro, pembrolizumab.

Year:

2025

Best percentage change from baseline in target lesions per RECIST version 1.1 in ( A ) arm 1 (IT MK-2118 monotherapy), ( B ) arm 2 (IT MK-2118 plus IV pembrolizumab), and ( C ) arm 4 (SC MK-2118 plus IV pembrolizumab).

Year:

2025

Arithmetic mean plasma concentration–time profiles of MK-2118 during cycle 1 following either IT (monotherapy and combination therapy with IV pembrolizumab) or SC (combination therapy with IV pembrolizumab) administration. MK-2118 concentration–time profiles for monotherapy and combination therapy arms were combined because there was substantial overlap in concentrations between arms.

Year:

2025

Purpose: We evaluated the noncyclic dinucleotide stimulator of IFN genes agonist MK-2118 ± pembrolizumab in participants with advanced solid tumors or lymphomas. Patients and Methods: This first-in-human study (NCT03249792) enrolled participants with refractory, advanced solid tumors or lymphomas. Participants received intratumoral (IT) MK-2118 100 to 20,000 μg (arm 1), IT MK-2118 900 to 15,000 μg plus intravenous (IV) pembrolizumab 200 mg every 3 weeks (arm 2), or subcutaneous (SC) MK-2118 5,000 to 150,000 μg plus IV pembrolizumab 200 mg every 3 weeks (arm 4); arm 3 (visceral injection of MK-2118) was not pursued. IT dosing used an accelerated titration design and modified toxicity probability interval method; SC dosing (arm 4) was started subsequent to arms 1 and 2. The primary objectives were safety/tolerability. MK-2118 pharmacokinetics was a secondary endpoint; objective responses and biomarkers were exploratory endpoints. Results: A total of 140 participants were enrolled (arm 1, n = 27; arm 2, n = 57; arm 4, n = 56). Grade 3/4 treatment-related adverse events occurred in 22%, 23%, and 11% of participants, respectively, but no maximum tolerated dose was identified up to MK-2118 20,000, 15,000, and 150,000 μg across the three arms. Dose-dependent increases in MK-2118 systemic exposure were observed following IT and subcutaneous administration. Objective responses were seen in 0%, 6%, and 4% of participants, respectively. IT MK-2118 led to dose-dependent changes in stimulator of interferon genes–based blood RNA expression levels, IFNγ, IFNγ-induced protein 10, and IL6; SC MK-2118 did not generate dose-related immune responses. Conclusions: IT MK-2118 ± pembrolizumab and SC MK-2118 plus pembrolizumab had manageable toxicity and limited antitumor activity. IT but not SC administration demonstrated systemic immune effects.

Year:

2025

Year:

2024

Collaborators (14)

David Braun

Assistant Professor, Principal Investigator

Yale University Yale Cancer Center

UNITED STATES
View details

Sandip Patel

Associate Professor

Moores Cancer Center, UC San Diego Health

UNITED STATES
View details

Mehmet Asim Bilen

Emory University School of Medicine

UNITED STATES
View details

Guarionex Joel DeCastro

Associate Professor

Columbia University

UNITED STATES
View details

Talia Golan

-

ISRAEL
View details

Casey Ager

Assistant Professor

Mayo Clinic Arizona

UNITED STATES
View details

Toni Choueiri

Director, Lank Center for Genitourinary Oncology

Dana-Farber Cancer Institute

UNITED STATES
View details

Michael Hurwitz

Associate Professor

Yale University School of Medicine

UNITED STATES
View details

Kelly Street

Assistant Professor

University of Southern California Keck School of Medicine

UNITED STATES
View details

Andrea Califano

Columbia University Irving Medical Center

UNITED STATES
View details

Timothy Yap

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Jason J. Luke

-

UNITED STATES
View details

Naomi B Haas

PI

University of Pennsylvania

UNITED STATES
View details

David McDermott

Beth Israel Deaconess Medical Center

UNITED STATES
View details